{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:40:53Z","timestamp":1781196053418,"version":"3.54.1"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Primary Sj\u00f6gren\u2019s syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. A cardinal pathogenetic feature of SS is B-cell hyperactivity, which has invited efforts on optimal B-cell targeted therapy, whereas conventional corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are restricted to symptomatic relief. As per the first EULAR recommendation for pSS patients published in 2020, regimens with monoclonal antibodies targeting B cells may be initiated in patients with severe, refractory systemic disease, notably rituximab (RTX), a mouse-derived monoclonal antibody that targets CD20 antigen and contributes to B-cell depletion. Nonetheless, the data available from clinical trials with RTX are often controversial. Despite the lack of promising results from two large RCTs, several positive clinical efficacies were demonstrated. This current review addressed the efficacy and safety of clinical trials available and elucidated the potential of RTX on the immune system, especially B and T cells. Furthermore, plausible explanations for the discrepancy in clinical data were also presented.<\/jats:p>","DOI":"10.3389\/fphar.2021.731122","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:42:01Z","timestamp":1630723321000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Rituximab Therapy for Primary Sj\u00f6gren\u2019s Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Yi Han","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21691401.2018.1449119","article-title":"A Developed Antibody-Drug Conjugate Rituximab-vcMMAE Shows a Potent Cytotoxic Activity against CD20-Positive Cell Line","volume":"46","author":"Abdollahpour-Alitappeh","year":"2018","journal-title":"Artif. Cell Nanomed Biotechnol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-hodgkin's Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/ard.2004.027128","article-title":"Successful Treatment of Refractory Anterior Scleritis in Primary Sjogren's Syndrome with Rituximab","volume":"64","author":"Ahmadi-Simab","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed Memory B Cell Recovery in Peripheral Blood and Lymphoid Tissue in Systemic Lupus Erythematosus after B Cell Depletion Therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of Immunoglobulin Levels, Infectious Risk, and Mortality with Rituximab and Hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B Cell Depletion Therapy Ameliorates Autoimmune Disease through Ablation of IL-6-producing B Cells","volume":"209","author":"Barr","year":"2012","journal-title":"J. Exp. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","article-title":"Rituximab-induced Serum Sickness Is More Frequent in Autoimmune Diseases as Compared to Hematological Malignancies: A French Nationwide Study","volume":"67","author":"Bayer","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/cei.12472","article-title":"Effect of Rituximab on B Cell Phenotype and Serum B Cell-Activating Factor Levels in Patients with Thrombotic Thrombocytopenic Purpura","volume":"179","author":"Becerra","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1182\/blood-2011-04-345579","article-title":"Human Memory B Cells Originate from Three Distinct Germinal center-dependent and -independent Maturation Pathways","volume":"118","author":"Berkowska","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj\u00f6gren's Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"R161","DOI":"10.1186\/ar3901","article-title":"B Lymphocyte-Typing for Prediction of Clinical Response to Rituximab","volume":"14","author":"Brezinschek","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2013.12.002","article-title":"The Effect of B-Cell Depletion Therapy on Serological Evidence of B-Cell and Plasmablast Activation in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment","volume":"50","author":"Cambridge","year":"2014","journal-title":"J. Autoimmun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1770565","DOI":"10.1080\/2162402x.2020.1770565","article-title":"A Rationally-Engineered IL-2 Improves the Antitumor Effect of Anti-CD20 Therapy","volume":"9","author":"Casades\u00fas","year":"2020","journal-title":"Oncoimmunology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1534\/genetics.116.192898","article-title":"The Neuropeptides FLP-2 and PDF-1 Act in Concert to Arouse Caenorhabditis elegans Locomotion","volume":"204","author":"Chen","year":"2016","journal-title":"Genetics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bjh.15110","article-title":"Ofatumumab Is a Feasible Alternative Anti-CD20 Therapy in Patients Intolerant of Rituximab","volume":"184","author":"Chen","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/annrheumdis-2012-202754","article-title":"Rituximab Modulates the Expression of IL-22 in the Salivary Glands of Patients with Primary Sjogren's Syndrome","volume":"72","author":"Ciccia","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/keu004","article-title":"Rituximab Modulates IL-17 Expression in the Salivary Glands of Patients with Primary Sj\u00f6gren's Syndrome","volume":"53","author":"Ciccia","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jaut.2015.11.002","article-title":"Blood and Salivary-Gland BAFF-Driven B-Cell Hyperactivity Is Associated to Rituximab Inefficacy in Primary Sj\u00f6gren's Syndrome","volume":"67","author":"Cornec","year":"","journal-title":"J. Autoimmun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/rheumatology\/kev114","article-title":"Development of the Sj\u00f6gren's Syndrome Responder Index, a Data-Driven Composite Endpoint for Assessing Treatment Efficacy","volume":"54","author":"Cornec","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0162787","DOI":"10.1371\/journal.pone.0162787","article-title":"High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sj\u00f6gren's Syndrome: Data from the TEARS Randomized Trial","volume":"11","author":"Cornec","year":"","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of Fatigue in Sj\u00f6gren Syndrome with Rituximab: Results of a Randomised, Double-Blind, Placebo-Controlled Pilot Study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s1470-2045(14)70005-1","article-title":"Pharmacokinetics and Safety of Subcutaneous Rituximab in Follicular Lymphoma (SABRINA): Stage 1 Analysis of a Randomised Phase 3 Study","volume":"15","author":"Davies","year":"2014","journal-title":"Lancet Oncol."},{"key":"B24","first-page":"490","article-title":"Sequential Therapy with Belimumab Followed by Rituximab in Sj\u00f6gren's Syndrome Associated with B-Cell Lymphoproliferation and Overexpression of BAFF: Evidence for Long-Term Efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1074\/jbc.273.1.344","article-title":"Rapid Redistribution of CD20 to a Low Density Detergent-Insoluble Membrane Compartment","volume":"273","author":"Deans","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1136\/annrheumdis-2015-208304","article-title":"Towards Personalised Treatment in Primary Sj\u00f6gren's Syndrome: Baseline Parotid Histopathology Predicts Responsiveness to Rituximab Treatment","volume":"75","author":"Delli","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/m13-1085","article-title":"Treatment of Primary Sj\u00f6gren Syndrome with Rituximab: a Randomized Trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren's Syndrome after Two Infusions of Rituximab (Anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/rheumatology\/kem164","article-title":"Repeated B-Cell Depletion in Clinical Practice","volume":"46","author":"Edwards","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling Effects of Rituximab in Lupus: Danger Ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular Cloning of the Human B Cell CD20 Receptor Predicts a Hydrophobic Protein with Multiple Transmembrane Domains","volume":"7","author":"Einfeld","year":"1988","journal-title":"Embo j"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1158\/1078-0432.Ccr-04-0525","article-title":"Combination Immunotherapy of B-Cell Non-hodgkin's Lymphoma with Rituximab and Interleukin-2: a Preclinical and Phase I Study","volume":"10","author":"Eisenbeis","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00447-20","article-title":"CD8+ T Cell Immunity Is Compromised by Anti-CD20 Treatment and Rescued by Interleukin-17A","volume":"11","author":"Fiocca Vernengo","year":"2020","journal-title":"mBio"},{"key":"B34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of Rituximab on a Salivary Gland Ultrasound Score in Primary Sj\u00f6gren's Syndrome: Results of the TRACTISS Randomised Double-Blind Multicentre Substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s12016-007-8028-z","article-title":"Should Rituximab Be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?","volume":"34","author":"Galarza","year":"2008","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1593\/tlo.10172","article-title":"Interleukin 22 Signaling Promotes Cell Growth in Mantle Cell Lymphoma","volume":"4","author":"Gelebart","year":"2011","journal-title":"Transl Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e59868","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sj\u00f6gren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1172\/jci14121","article-title":"Association of BAFF\/BLyS Overexpression and Altered B Cell Differentiation with Sj\u00f6gren's Syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J. Clin. Invest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A Review of the Current Use of Rituximab in Autoimmune Diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int. Immunopharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/ard.2007.074203","article-title":"Exocrine Function in Primary Sj\u00f6gren Syndrome: Natural Course and Prognostic Factors","volume":"67","author":"Haldorsen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/annrheumdis-2011-201189","article-title":"Persistence of Immunoglobulin-Producing Cells in Parotid Salivary Glands of Patients with Primary Sj\u00f6gren's Syndrome after B Cell Depletion Therapy","volume":"71","author":"Hamza","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.4049\/jimmunol.168.7.3165","article-title":"Germinal center B Cells Constitute a Predominant Physiological Source of IL-4: Implication for Th2 Development In Vivo","volume":"168","author":"Johansson-Lindbom","year":"2002","journal-title":"J. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/art.39088","article-title":"Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sj\u00f6gren's Syndrome","volume":"67","author":"Jousse-Joulin","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B Cell-Activating Factor of the TNF Family (BAFF) after Rituximab Treatment: Insights into a New Regulating System of BAFF Production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","article-title":"Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review","volume":"5","author":"Levin","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of Long-Lived Autoreactive Plasma Cells in the Spleen of Primary Warm Auto-Immune Hemolytic Anemia Patients Treated with Rituximab","volume":"62","author":"Mah\u00e9vas","year":"2015","journal-title":"J. Autoimmun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: Mechanism of Action and Resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMcp170251410.1056\/NEJMc1804598","article-title":"Primary Sj\u00f6gren's Syndrome","volume":"379","author":"Mariette","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and where Are We Going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front. Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1503\/cmaj.12203710.1002\/acr.22216","article-title":"Elevated IgG4 Serum Levels Among Primary Sj\u00f6gren's Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease?","volume":"66","author":"Mavragani","year":"2014","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A Unique Population of IgG-Expressing Plasma Cells Lacking CD19 Is Enriched in Human Bone Marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of Rituximab Treatment in Primary Sj\u00f6gren's Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","article-title":"Responsiveness of Disease Activity Indices ESSPRI and ESSDAI in Patients with Primary Sj\u00f6gren's Syndrome Treated with Rituximab","volume":"71","author":"Meiners","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1002\/art.24722","article-title":"Delayed Acquisition of Somatic Hypermutations in Repopulated IGD+CD27+ Memory B Cell Receptors after Rituximab Treatment","volume":"60","author":"Muhammad","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab Mediates a strong Elevation of B-Cell-Activating Factor Associated with Increased Pathogen-specific IgG but Not Autoantibodies in Pemphigus Vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ctrv.2015.05.007","article-title":"Action and Resistance of Monoclonal CD20 Antibodies Therapy in B-Cell Non-hodgkin Lymphomas","volume":"41","author":"P\u00e9rez-Callejo","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1002\/art.24903","article-title":"Clinical and Histologic Evidence of Salivary Gland Restoration Supports the Efficacy of Rituximab Treatment in Sj\u00f6gren's Syndrome","volume":"60","author":"Pijpe","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab Treatment in Patients with Primary Sj\u00f6gren's Syndrome: an Open-Label Phase II Study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B62","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","article-title":"Serum Levels of BAFF, but Not APRIL, Are Increased after Rituximab Treatment in Patients with Primary Sjogren's Syndrome: Data from a Placebo-Controlled Clinical Trial","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR Recommendations for the Management of Sj\u00f6gren's Syndrome with Topical and Systemic Therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","article-title":"Topical and Systemic Medications for the Treatment of Primary Sj\u00f6gren's Syndrome","volume":"8","author":"Ramos-Casals","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar2789","article-title":"Short- and Long-Term Effects of Anti-CD20 Treatment on B Cell Ontogeny in Bone Marrow of Patients with Rheumatoid Arthritis","volume":"11","author":"Rehnberg","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 Therapy in Patients with Rheumatoid Arthritis: Predictors of Response and B Cell Subset Regeneration after Repeated Treatment","volume":"58","author":"Roll","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B Cell Subsets after Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B68","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The Role of APRIL and BAFF in Lymphocyte Activation","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's Syndrome Disease Activity index: Development of a Consensus Systemic Disease Activity index for Primary Sjogren's Syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): Development of a Consensus Patient index for Primary Sjogren's Syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fimmu.2016.00077","article-title":"B Cell Development in the Bone Marrow Is Regulated by Homeostatic Feedback Exerted by Mature B Cells","volume":"7","author":"Shahaf","year":"2016","journal-title":"Front. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/00003072-200202000-00019","article-title":"F-18 FDG Positron Emission Tomography Demonstrates Resolution of Non-hodgkin's Lymphoma of the Parotid Gland in a Patient with Sjogren's Syndrome: before and after Anti-CD20 Antibody Rituximab Therapy","volume":"27","author":"Shih","year":"2002","journal-title":"Clin. Nucl. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-065X.2008.00627.x","article-title":"Understanding the Mechanistic Basis in Rheumatoid Arthritis for Clinical Response to Anti-CD20 Therapy: the B-Cell Roadblock Hypothesis","volume":"223","author":"Silverman","year":"2008","journal-title":"Immunol. Rev."},{"key":"B74","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/art.11109","article-title":"Improvement in Sj\u00f6gren's Syndrome Following Therapy with Rituximab for Marginal Zone Lymphoma","volume":"49","author":"Somer","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B75","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13075-018-1760-3","article-title":"The Risks of Cancer Development in Systemic Lupus Erythematosus (SLE) Patients: a Systematic Review and Meta-Analysis","volume":"20","author":"Song","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/art.37850","article-title":"Rituximab Therapy for Primary Sj\u00f6gren's Syndrome: an Open-Label Clinical Trial and Mechanistic Analysis","volume":"65","author":"St Clair","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B78","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of Long-Term B-Cell Depletion in Refractory Rheumatoid Arthritis Patients Preferentially Affects Autoreactive More Than Protective Humoral Immunity","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential Effects on BAFF and APRIL Levels in Rituximab-Treated Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/08916934.2014.914174","article-title":"Reconstitution of the Peripheral B Lymphocyte Compartment in Patients with ANCA-Associated Vasculitides Treated with Rituximab for Relapsing or Refractory Disease","volume":"47","author":"Venhoff","year":"2014","journal-title":"Autoimmunity"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2174\/138920112802273254","article-title":"Current and Future Challenges in Primary Sj\u00f6gren's Syndrome","volume":"13","author":"Vissink","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of Rituximab for Pemphigus: a Systematic Review and Meta-Analysis of Different Regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11095-019-2624-5","article-title":"Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-hodgkin's Lymphoma","volume":"36","author":"Yonezawa","year":"2019","journal-title":"Pharm. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.731122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:42:04Z","timestamp":1630723324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.731122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":80,"alternative-id":["10.3389\/fphar.2021.731122"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.731122","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"article-number":"731122"}}